Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.

Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins.

Chen S, Le WD, Xie WJ, Alexianu ME, Engelhardt JI, Siklós L, Appel SH.

Arch Neurol. 1998 Aug;55(8):1075-80.

PMID:
9708957
3.

Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.

Zecca L, Wilms H, Geick S, Claasen JH, Brandenburg LO, Holzknecht C, Panizza ML, Zucca FA, Deuschl G, Sievers J, Lucius R.

Acta Neuropathol. 2008 Jul;116(1):47-55. doi: 10.1007/s00401-008-0361-7. Epub 2008 Mar 15.

PMID:
18343932
4.

[Effects of electroacupuncture on behaviors and dopaminergic neurons in the rat of Parkinson's disease].

Ma J, Wang YC, Gan SY.

Zhongguo Zhen Jiu. 2006 Sep;26(9):655-7. Chinese.

PMID:
17036487
5.

Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, Vance JM.

Arch Neurol. 2005 Jun;62(6):917-21.

PMID:
15956162
6.

Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease.

Shergill JK, Cammack R, Cooper CE, Cooper JM, Mann VM, Schapira AH.

Biochem Biophys Res Commun. 1996 Nov 12;228(2):298-305.

PMID:
8920909
7.

Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts.

Ma SY, Röyttä M, Rinne JO, Collan Y, Rinne UK.

J Neurol Sci. 1997 Oct 3;151(1):83-7.

PMID:
9335015
8.

On the question of apoptosis in the parkinsonian substantia nigra.

Kösel S, Egensperger R, von Eitzen U, Mehraein P, Graeber MB.

Acta Neuropathol. 1997 Feb;93(2):105-8.

PMID:
9039456
9.

[Protective effects of doxycycline upon dopaminergic neuron in LPS-induced rat model of Parkinson's disease].

Wang PQ, Sun SG, Qiao X.

Zhonghua Yi Xue Za Zhi. 2009 May 19;89(19):1346-50. Chinese.

PMID:
19615192
10.

p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.

Mogi M, Kondo T, Mizuno Y, Nagatsu T.

Neurosci Lett. 2007 Feb 27;414(1):94-7. Epub 2006 Dec 29.

PMID:
17196747
11.
12.

Anti-melanin antibodies are increased in sera in Parkinson's disease.

Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DK, Blackie J, Corbett A, Joffe R, Fung VS, Morris J, Riederer P, Gerlach M, Halliday GM.

Exp Neurol. 2009 Jun;217(2):297-301. doi: 10.1016/j.expneurol.2009.03.002. Epub 2009 Mar 13.

PMID:
19289120
13.

An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease.

Yoritaka A, Hattori N, Mori H, Kato K, Mizuno Y.

J Neurol Sci. 1997 May 29;148(2):181-6. Erratum in: J Neurol Sci 1997 Sep 10;150(2):177-8.

PMID:
9129114
14.
15.
16.

Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death.

Bossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, Swaab DF, Verhaagen J.

Brain Pathol. 2009 Jan;19(1):91-107. doi: 10.1111/j.1750-3639.2008.00171.x. Epub 2008 May 7.

PMID:
18462474
18.

Pathogenesis of nigral cell death in Parkinson's disease.

Przedborski S.

Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S3-7. Review.

PMID:
15885625
19.

Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.

Liu CQ, Chen Z, Liu FX, Hu DN, Luo JH.

Neuropharmacology. 2007 Dec;53(7):832-41. Epub 2007 Aug 25.

PMID:
17919665
20.

Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging.

Minati L, Grisoli M, Carella F, De Simone T, Bruzzone MG, Savoiardo M.

AJNR Am J Neuroradiol. 2007 Feb;28(2):309-13.

Supplemental Content

Support Center